Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ViroMissile, Inc.
Tizona Therapeutics, Inc
Innate Pharma
NeoTX Therapeutics Ltd.
Hangzhou DAC Biotechnology Co., Ltd.
Eli Lilly and Company
Columbia University
Theratechnologies
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Pfizer
NGM Biopharmaceuticals, Inc
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Ludwig Institute for Cancer Research
Imperial College London
MacroGenics
MacroGenics
Abramson Cancer Center at Penn Medicine
Celgene
Viralytics
Threshold Pharmaceuticals
Santa Maria Biotherapeutics
University of Southern California
M.D. Anderson Cancer Center
BIND Therapeutics
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
ImmunoFrontier, Inc.
Bristol-Myers Squibb
Life Molecular Imaging SA
University of Chicago
Calando Pharmaceuticals
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Rutgers, The State University of New Jersey